Consistent with systemic IL-2 therapy, β-cell-specific IL-2 delivery persistently suppressed β-cell autoimmunity and provided long-term protection against diabetes onset in both preclinical and advanced disease stages. The gene discussed is IL2; the disease is diabetes mellitus.